Comment on

• Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.

  Corre J, Vincent L, Moreau P, Hebraud B, Hulin C, Béné MC, Broijl A, Caillot D, Delforge M, Dejoie T, Facon T, Lambert J, Leleu X, Macro M, Perrot A, Zweegman S, Filleron T, Cabarrou B, van de Donk NWCJ, Mahéo S, Hua W, Wang J, Krevvata M, Vanquickelberghe V, de Boer C, Tuozzo A, Borgsten F, Rowe M, Carson R, Wuilleme S, Sonneveld P. Corre J, et al. Blood. 2025 Aug 7;146(6):679-692. doi: 10.1182/blood.2024027620. Blood. 2025. PMID: 40127397 Clinical Trial.